Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where R. Dunn is active.

Publication


Featured researches published by R. Dunn.


Urology | 2015

Minimally important difference for the Expanded Prostate Cancer Index Composite Short Form.

Ted A. Skolarus; R. Dunn; Martin G. Sanda; Peter Chang; Thomas K. Greenfield; Mark S. Litwin; John T. Wei; Meredith M. Regan; Larry Hembroff; Dan Hamstra; Rodney L. Dunn; Laurel Northouse; David P. Wood; Eric A. Klein; Jay P. Ciezki; Jeff M. Michalski; Gerald L. Andriole; Chris Saigal; Louis L. Pisters; Deborah A. Kuban; Howard M. Sandler; Jim C. Hu; Adam S. Kibel; Douglas M. Dahl; Anthony L. Zietman; Andrew J. Wagner; Irving D. Kaplan

OBJECTIVEnTo establish a score threshold that constitutes a clinically relevant change for each domain of the Expanded Prostate Cancer Index Composite (EPIC) Short Form (EPIC-26). Although its use in clinical practice and clinical trials has increased worldwide, the clinical interpretation of this 26-item disease-specific patient-reported quality of life questionnaire for men with localized prostate cancer would be facilitated by characterization of score thresholds for clinically relevant change (the minimally important differences [MIDs]).nnnMETHODSnWe used distribution- and anchor-based approaches to establish the MID range for each EPIC-26 domain (urinary, sexual, bowel, and vitality/hormonal) based on a prospective multi-institutional cohort of 1201 men treated for prostate cancer between 2003 and 2006 and followed up for 3xa0years after treatment. For the anchor-based approach, we compared within-subject and between-subject score changes for each domain to an external anchor measure of overall cancer treatment satisfaction.nnnRESULTSnWe found the bowel and vitality/hormonal domains to have the lowest MID range (a 4-6 point change should be considered clinically relevant), whereas the sexual domain had the greatest MID values (10-12). Urinary incontinence appeared to have a greater MID range (6-9) than the urinary irritation/obstruction domain (5-7).nnnCONCLUSIONnUsing 2 independent approaches, we established the MIDs for each EPIC-26 domain. A definition of these MID values is essential for the researcher or clinician to understand when changes in symptom burden among prostate cancer survivors are clinically relevant.


International Journal of Radiation Oncology Biology Physics | 2017

External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life

Martin G. Sanda; J Liu; Ningying Wu; Daniel A. Hamstra; John T. Wei; R. Dunn; Eric A. Klein; Howard M. Sandler; Christopher S. Saigal; Mark S. Litwin; Deborah A. Kuban; Larry Hembroff; Meredith M. Regan; Peter Chang; Meredith Regan; Dan Hamstra; Rodney L. Dunn; Laurel Northouse; David P. Wood; Jay P. Ciezki; Jeff M. Michalski; Gerald L. Andriole; Thomas K. Greenfield; Louis L. Pisters; Deborah Kuban; Jim C. Hu; Adam S. Kibel; Douglas M. Dahl; Anthony L. Zietman; Irving D. Kaplan

PURPOSEnThe long-term effects of neoadjuvant androgen deprivation therapy (NADT) with radiation therapy on participant-reported health-related quality of life (HRQOL) have not been characterized in prospective multicenter studies. We evaluated HRQOL for 2xa0years among participants undergoing radiation therapy (RT) with or without NADT for newly diagnosed, early-stage prostate cancer.nnnMETHODS AND MATERIALSnWe analyzed longitudinal cohort data from the Prostate Cancer Outcomes and Satisfaction with Treatment Quality Assessment Consortium to ascertain the HRQOL trajectory of men receiving NADT with external beam RT (EBRT) or brachytherapy. HRQOL was measured using the expanded prostate cancer index composite 26-item questionnaire at 2, 6, 12, and 24xa0months after the initiation of NADT. We used the χ2 or Fisher exact test to compare the shift in percentages between groups that did or did not receive NADT. Analyses were conducted at the 2-sided 5% significance level.nnnRESULTSnFor subjects receiving EBRT, questions regarding the ability to have an erection, ability to reach an orgasm, quality of erections, frequency of erections, ability to function sexually, and lack of energy were in a significantly worse dichotomized category for the patients receiving NADT. Comparing the baseline versus 24-month outcomes, 24%, 23%, and 30% of participants receiving EBRT plus NADT shifted to the worse dichotomized category for the ability to reach an orgasm, quality of erections, and ability to function sexually compared with 14%, 13%, and 16% in the EBRT group, respectively.nnnCONCLUSIONSnCompared with baseline, at 2xa0years, participants receiving NADT plus EBRT compared with EBRT alone had worse HRQOL, as measured by the ability to reach orgasm, quality of erections, and ability to function sexually. However, no difference was found in the ability to have an erection, frequency of erections, overall sexual function, hot flashes, breast tenderness/enlargement, depression, lack of energy, or change in body weight. The improved survival in intermediate- and high-risk patients receiving NADT and EBRT necessitates pretreatment counseling of the HRQOL effect of NADT and EBRT.


Urology | 2005

Preliminary study of immunomagnetic quantification of circulating tumor cells in patients with advanced disease

Bert T. Chen; Robert D. Loberg; Neeley Ck; O'Hara Sm; Gross S; Doyle G; R. Dunn; Linda M. Kalikin; Kenneth J. Pienta


International Journal of Radiation Oncology Biology Physics | 2000

Health related quality of life following 3D conformal external beam radiotherapy: treatment factors influence patient-reported outcome

Howard M. Sandler; R. Dunn; John T. Wei; Patrick W. McLaughlin; G.T Henning; Martin G. Sanda


International Journal of Radiation Oncology Biology Physics | 2006

2204 : Early Complications Following Contemporary Brachytherapy for Prostate Cancer in a Multi-Institutional Study at High Volume Health Centers in the US

J.M. Michalski; Jay P. Ciezki; Irving D. Kaplan; Deborah A. Kuban; Patrick W. McLaughlin; Howard M. Sandler; Steve P. Lee; R. Dunn; John T. Wei; Martin G. Sanda


International Journal of Radiation Oncology Biology Physics | 2014

Patient-Reported Outcomes for Quality of Life (QOL) by Expanded Prostate Cancer Index (EPIC) 15 Years Posttreatment

Jessica Zhou; Stephanie Daignault-Newton; David C. Miller; John T. Wei; R. Dunn; Skyler B. Johnson; William C. Jackson; H. Imam; N. Kazzi; Patrick W. McLaughlin; Howard M. Sandler; Martin G. Sanda; Daniel A. Hamstra


International Journal of Radiation Oncology Biology Physics | 2006

2241 : Early Complications Following Contemporary Radiotherapy for Prostate Cancer in a Multi-Institutional Study at High-Volume Health Care Centers in the United States

Carlos López; J.M. Michalski; Deborah A. Kuban; A. Mahadevan; Irving D. Kaplan; Steve P. Lee; Anthony L. Zietman; W.W. Suh; R. Dunn; Howard M. Sandler


Urology | 2005

Quality assurance in urologic oncology: a radical prostatectomy experience of 2254 cases

James E. Montie; John T. Wei; David Miller; R. Dunn


International Journal of Radiation Oncology Biology Physics | 2005

Neoadjuvant Hormone Therapy (NHT) Leads to Immediate Impairment of Vitality/Hormonal and Sexual Quality of Life: Results of a Multi-Center Prospective Study

J.M. Michalski; John T. Wei; R. Dunn; A. Mahadevan; Howard M. Sandler; Chris Saigal; Deborah A. Kuban; Louis L. Pisters; Eric A. Klein; Mark S. Litwin; Larry Hembroff; Martin G. Sanda


International Journal of Radiation Oncology Biology Physics | 2004

Cause-specific survival is high following radiotherapy or surgery for Gleason score 8–10 prostate cancer

Daniel A. Hamstra; R. Dunn; John T. Wei; James E. Montie; Martin G. Sanda; Howard M. Sandler

Collaboration


Dive into the R. Dunn's collaboration.

Top Co-Authors

Avatar

Howard M. Sandler

Cedars-Sinai Medical Center

View shared research outputs
Top Co-Authors

Avatar

John T. Wei

University of Michigan

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Deborah A. Kuban

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Irving D. Kaplan

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

J.M. Michalski

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge